Aone

gmail : a1tradekorea BOTULAX 200 IU , What is Botulax? Botulax contains 200 units (U) of Clostridium botulinum toxin type A, 0.5 milligrams of albumin (human)and 0.9 milligrams of sodium chloride in a sterile, vacuum-dried from without a preservative. Botulinum toxin type A neutroxin: purified from Clostridium botulinum type A Albumin: Human serum albumin,bulking and stabilizing agent and adhesion reducer. KP grade NaCl: Bulking agent and keeping isotonicity during formulation KP grade Developmental status: 2007.5: reported nonclinical study 2008.3: reported clinically study Phase l 2009.7: Finished Phase lll clinically study Characteristics of Botulax:Higher specific activity than those of other company’s botolinum toxin products by improving lyophilization process Facility: BOTULAX 200 IU Mode of action Botulinum Toxin Type A blocks signals from the nerves to the muscles. The injected muscle can no longer contract, which causes the wrinkles to relax and soften. It is most often used on forehead lines, crow’s feet (lines around the eye) and frown lines. BOTULAX 200 IU Features and Benefits Botulax guarantees high patient satisfaction. Potency variation is strictly controlled to within 91-115 units/ vial, more stringent than the legally required range. BOTULAX 200 IU Size of toxin complex is 900kDa, minimize spread of botulinum toxin outside of the injection site. Such large and homogeneous size of the toxin complex ensures precise and uniform effect at the time of injection, guaranteeing high patient satisfaction with Botulax BOTULAX 200 IU , What is Botulax? Botulax contains 200 units (U) of Clostridium botulinum toxin type A, 0.5 milligrams of albumin (human)and 0.9 milligrams of sodium chloride in a sterile, vacuum-dried from without a preservative. Botulinum toxin type A neutroxin: purified from Clostridium botulinum type A Albumin: Human serum albumin,bulking and stabilizing agent and adhesion reducer. KP grade NaCl: Bulking agent and keeping isotonicity during formulation KP grade Developmental status: 2007.5: reported nonclinical study 2008.3: reported clinically study Phase l 2009.7: Finished Phase lll clinically study Characteristics of Botulax:Higher specific activity than those of other company’s botolinum toxin products by improving lyophilization process Facility: